CA2577442A1 - Pde5 inhibitor compositions and methods for treating cardiac indications - Google Patents

Info

Publication number

CA2577442A1

CA2577442A1 CA002577442A CA2577442A CA2577442A1 CA 2577442 A1 CA2577442 A1 CA 2577442A1 CA 002577442 A CA002577442 A CA 002577442A CA 2577442 A CA2577442 A CA 2577442A CA 2577442 A1 CA2577442 A1 CA 2577442A1

Authority

CA

Canada

Prior art keywords

cardiac

pde5 inhibitor

composition

sildenafil

inhibitor

Prior art date

2004-08-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 128
• 230000000747 cardiac effect Effects 0.000 title claims abstract description 124
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title claims abstract description 121
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 title claims abstract description 121
• 239000000203 mixture Substances 0.000 title claims abstract description 104
• 230000000694 effects Effects 0.000 claims description 159
• 210000002216 heart Anatomy 0.000 claims description 136
• 238000011282 treatment Methods 0.000 claims description 90
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 73
• 238000007634 remodeling Methods 0.000 claims description 70
• 230000006870 function Effects 0.000 claims description 69
• 206010020880 Hypertrophy Diseases 0.000 claims description 58
• 230000004217 heart function Effects 0.000 claims description 57
• 208000006029 Cardiomegaly Diseases 0.000 claims description 54
• 239000003112 inhibitor Substances 0.000 claims description 53
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 52
• 210000000107 myocyte Anatomy 0.000 claims description 51
• 230000014509 gene expression Effects 0.000 claims description 50
• 230000004913 activation Effects 0.000 claims description 41
• 230000003205 diastolic effect Effects 0.000 claims description 41
• 230000002829 reductive effect Effects 0.000 claims description 41
• 238000012360 testing method Methods 0.000 claims description 39
• 239000003795 chemical substances by application Substances 0.000 claims description 35
• 102000004631 Calcineurin Human genes 0.000 claims description 34
• 108010042955 Calcineurin Proteins 0.000 claims description 34
• 230000001413 cellular effect Effects 0.000 claims description 31
• 230000004075 alteration Effects 0.000 claims description 30
• 210000004413 cardiac myocyte Anatomy 0.000 claims description 28
• 206010019280 Heart failures Diseases 0.000 claims description 26
• 230000002107 myocardial effect Effects 0.000 claims description 24
• 230000035882 stress Effects 0.000 claims description 24
• 238000003556 assay Methods 0.000 claims description 19
• 230000001419 dependent effect Effects 0.000 claims description 18
• 210000004165 myocardium Anatomy 0.000 claims description 18
• 230000037361 pathway Effects 0.000 claims description 17
• 230000011664 signaling Effects 0.000 claims description 17
• 230000002459 sustained effect Effects 0.000 claims description 17
• 230000002265 prevention Effects 0.000 claims description 15
• 206010020772 Hypertension Diseases 0.000 claims description 14
• 230000010343 cardiac dilation Effects 0.000 claims description 14
• 238000002592 echocardiography Methods 0.000 claims description 14
• 108060006633 protein kinase Proteins 0.000 claims description 14
• 210000005242 cardiac chamber Anatomy 0.000 claims description 13
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 12
• 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 12
• 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 12
• 230000000302 ischemic effect Effects 0.000 claims description 12
• 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims description 11
• 102000005741 Metalloproteases Human genes 0.000 claims description 11
• 108010006035 Metalloproteases Proteins 0.000 claims description 11
• 101150111584 RHOA gene Proteins 0.000 claims description 11
• 238000009472 formulation Methods 0.000 claims description 11
• 208000015210 hypertensive heart disease Diseases 0.000 claims description 11
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 10
• 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 10
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 10
• 206010002906 aortic stenosis Diseases 0.000 claims description 9
• 108010041788 rho-Associated Kinases Proteins 0.000 claims description 9
• 102000000568 rho-Associated Kinases Human genes 0.000 claims description 9
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 8
• 102000001253 Protein Kinase Human genes 0.000 claims description 8
• 230000036772 blood pressure Effects 0.000 claims description 8
• 230000002708 enhancing effect Effects 0.000 claims description 8
• 239000003226 mitogen Substances 0.000 claims description 8
• 229910019142 PO4 Inorganic materials 0.000 claims description 7
• 230000004872 arterial blood pressure Effects 0.000 claims description 7
• 230000002644 neurohormonal effect Effects 0.000 claims description 7
• 230000036542 oxidative stress Effects 0.000 claims description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
• 239000010452 phosphate Substances 0.000 claims description 7
• 238000013268 sustained release Methods 0.000 claims description 7
• 239000012730 sustained-release form Substances 0.000 claims description 7
• GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 claims description 6
• 101001011364 Acyrthosiphon pisum secondary endosymbiont phage 1 Endolysin Proteins 0.000 claims description 6
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 6
• 101000666359 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB2 Proteins 0.000 claims description 6
• 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 claims description 6
• 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 claims description 6
• 206010016803 Fluid overload Diseases 0.000 claims description 6
• 101000942315 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Cyclin-dependent kinases regulatory subunit Proteins 0.000 claims description 6
• 230000004071 biological effect Effects 0.000 claims description 6
• 229950007002 phosphocreatine Drugs 0.000 claims description 6
• 230000002685 pulmonary effect Effects 0.000 claims description 6
• 230000024883 vasodilation Effects 0.000 claims description 6
• 238000002595 magnetic resonance imaging Methods 0.000 claims description 5
• 208000010125 myocardial infarction Diseases 0.000 claims description 5
• 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 claims description 4
• 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 claims description 4
• 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 claims description 4
• 230000036284 oxygen consumption Effects 0.000 claims description 4
• 101800001318 Capsid protein VP4 Proteins 0.000 claims description 3
• 101150098694 PDE5A gene Proteins 0.000 claims description 3
• 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 claims description 3
• 238000011976 chest X-ray Methods 0.000 claims description 3
• 210000003205 muscle Anatomy 0.000 claims description 3
• 238000002600 positron emission tomography Methods 0.000 claims description 3
• 238000003860 storage Methods 0.000 claims description 3
• 229960001456 adenosine triphosphate Drugs 0.000 claims description 2
• 230000009795 fibrotic process Effects 0.000 claims description 2
• 230000004907 flux Effects 0.000 claims description 2
• 229910052816 inorganic phosphate Inorganic materials 0.000 claims description 2
• 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 1
• 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 1
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 473
• 229960003310 sildenafil Drugs 0.000 description 238
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 70
• 125000004432 carbon atom Chemical group C* 0.000 description 65
• 125000000217 alkyl group Chemical group 0.000 description 60
• 230000005764 inhibitory process Effects 0.000 description 60
• 229960001089 dobutamine Drugs 0.000 description 59
• JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 58
• -1 phospho Chemical class 0.000 description 56
• 230000004044 response Effects 0.000 description 48
• 230000001965 increasing effect Effects 0.000 description 40
• 229940039009 isoproterenol Drugs 0.000 description 40
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 39
• 108090000623 proteins and genes Proteins 0.000 description 38
• 239000000902 placebo Substances 0.000 description 35
• 229940068196 placebo Drugs 0.000 description 35
• 150000001875 compounds Chemical class 0.000 description 32
• 239000003814 drug Substances 0.000 description 32
• 238000004458 analytical method Methods 0.000 description 29
• 229910052739 hydrogen Inorganic materials 0.000 description 29
• 210000004027 cell Anatomy 0.000 description 28
• 230000000638 stimulation Effects 0.000 description 28
• 229940079593 drug Drugs 0.000 description 27
• 125000003545 alkoxy group Chemical group 0.000 description 26
• 239000001257 hydrogen Substances 0.000 description 26
• 102000004169 proteins and genes Human genes 0.000 description 26
• 241000699670 Mus sp. Species 0.000 description 25
• 239000003981 vehicle Substances 0.000 description 25
• 230000002861 ventricular Effects 0.000 description 25
• 230000007423 decrease Effects 0.000 description 22
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 22
• 241001465754 Metazoa Species 0.000 description 21
• 230000008859 change Effects 0.000 description 21
• 229960001802 phenylephrine Drugs 0.000 description 20
• 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 19
• 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 19
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 19
• 229960000835 tadalafil Drugs 0.000 description 19
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 19
• 230000001684 chronic effect Effects 0.000 description 18
• 235000018102 proteins Nutrition 0.000 description 18
• 229910052736 halogen Inorganic materials 0.000 description 17
• 150000002367 halogens Chemical group 0.000 description 17
• 125000000623 heterocyclic group Chemical group 0.000 description 17
• 229910052757 nitrogen Inorganic materials 0.000 description 17
• 125000003118 aryl group Chemical group 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
• 229910052791 calcium Inorganic materials 0.000 description 15
• 239000011575 calcium Substances 0.000 description 15
• 229920001451 polypropylene glycol Polymers 0.000 description 15
• 150000003254 radicals Chemical class 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 14
• 238000011049 filling Methods 0.000 description 14
• 230000000877 morphologic effect Effects 0.000 description 14
• 125000001424 substituent group Chemical group 0.000 description 14
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 13
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 13
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 13
• 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 13
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 13
• 208000019622 heart disease Diseases 0.000 description 13
• 125000005842 heteroatom Chemical group 0.000 description 13
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 12
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 12
• 150000002431 hydrogen Chemical class 0.000 description 12
• 210000004072 lung Anatomy 0.000 description 12
• 230000003204 osmotic effect Effects 0.000 description 12
• 229910052717 sulfur Inorganic materials 0.000 description 12
• 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 11
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
• 230000001800 adrenalinergic effect Effects 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 230000005754 cellular signaling Effects 0.000 description 11
• 125000000753 cycloalkyl group Chemical group 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 210000005003 heart tissue Anatomy 0.000 description 11
• 230000000004 hemodynamic effect Effects 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000005259 measurement Methods 0.000 description 11
• 229920000642 polymer Polymers 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 238000001262 western blot Methods 0.000 description 11
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 10
• 230000010339 dilation Effects 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 238000011534 incubation Methods 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 239000011159 matrix material Substances 0.000 description 10
• 230000007246 mechanism Effects 0.000 description 10
• ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 10
• 230000036470 plasma concentration Effects 0.000 description 10
• 230000003389 potentiating effect Effects 0.000 description 10
• 238000010186 staining Methods 0.000 description 10
• 241000701161 unidentified adenovirus Species 0.000 description 10
• 108020001621 Natriuretic Peptide Proteins 0.000 description 9
• 102000004571 Natriuretic peptide Human genes 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 239000000499 gel Substances 0.000 description 9
• 238000011068 loading method Methods 0.000 description 9
• 239000000692 natriuretic peptide Substances 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 150000003839 salts Chemical class 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 208000020446 Cardiac disease Diseases 0.000 description 8
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 8
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 8
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 8
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
• 125000004122 cyclic group Chemical group 0.000 description 8
• 230000001969 hypertrophic effect Effects 0.000 description 8
• 238000003384 imaging method Methods 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 238000001000 micrograph Methods 0.000 description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
• 206010016654 Fibrosis Diseases 0.000 description 7
• 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 7
• 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 108091000080 Phosphotransferase Proteins 0.000 description 7
• 238000000540 analysis of variance Methods 0.000 description 7
• 230000004761 fibrosis Effects 0.000 description 7
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 7
• 238000001802 infusion Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 239000012669 liquid formulation Substances 0.000 description 7
• 230000036581 peripheral resistance Effects 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 102000020233 phosphotransferase Human genes 0.000 description 7
• 230000036316 preload Effects 0.000 description 7
• 230000000284 resting effect Effects 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 238000004904 shortening Methods 0.000 description 7
• XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 102000013382 Gelatinases Human genes 0.000 description 6
• 108010026132 Gelatinases Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• 108060001084 Luciferase Proteins 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• 241000220317 Rosa Species 0.000 description 6
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 6
• 229910001424 calcium ion Inorganic materials 0.000 description 6
• 230000008602 contraction Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 201000010099 disease Diseases 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 229940100601 interleukin-6 Drugs 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 229910021645 metal ion Inorganic materials 0.000 description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 230000002441 reversible effect Effects 0.000 description 6
• 210000002235 sarcomere Anatomy 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 210000002303 tibia Anatomy 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 229960002381 vardenafil Drugs 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 229910006069 SO3H Inorganic materials 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 230000003139 buffering effect Effects 0.000 description 5
• 229920002678 cellulose Polymers 0.000 description 5
• 230000035487 diastolic blood pressure Effects 0.000 description 5
• 239000000539 dimer Substances 0.000 description 5
• 238000002875 fluorescence polarization Methods 0.000 description 5
• 239000000017 hydrogel Substances 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000001991 pathophysiological effect Effects 0.000 description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000002924 silencing RNA Substances 0.000 description 5
• 230000035488 systolic blood pressure Effects 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 102100024317 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Human genes 0.000 description 4
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
• 101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000001746 atrial effect Effects 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 230000009084 cardiovascular function Effects 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 238000011278 co-treatment Methods 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 230000003292 diminished effect Effects 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 230000001605 fetal effect Effects 0.000 description 4
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
• 150000004677 hydrates Chemical class 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 238000007427 paired t-test Methods 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 230000000750 progressive effect Effects 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 230000008093 supporting effect Effects 0.000 description 4
• 230000001629 suppression Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
• 238000011870 unpaired t-test Methods 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 208000010228 Erectile Dysfunction Diseases 0.000 description 3
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
• 102000001267 GSK3 Human genes 0.000 description 3
• 108060006662 GSK3 Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010061216 Infarction Diseases 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 108091007960 PI3Ks Proteins 0.000 description 3
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
• 101150099493 STAT3 gene Proteins 0.000 description 3
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000000048 adrenergic agonist Substances 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 230000003466 anti-cipated effect Effects 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 150000003943 catecholamines Chemical class 0.000 description 3
• 230000008828 contractile function Effects 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
• 239000004205 dimethyl polysiloxane Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 235000014304 histidine Nutrition 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000012744 immunostaining Methods 0.000 description 3
• 201000001881 impotence Diseases 0.000 description 3
• 238000007925 in vitro drug release testing Methods 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
• 239000003094 microcapsule Substances 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 239000003068 molecular probe Substances 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 230000004660 morphological change Effects 0.000 description 3
• NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 3
• 230000008520 organization Effects 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 238000004321 preservation Methods 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 238000001243 protein synthesis Methods 0.000 description 3
• 239000011435 rock Substances 0.000 description 3
• DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 3
• 239000013598 vector Substances 0.000 description 3
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
• FOSISNXVGQBIAP-ALCCZGGFSA-N (Z)-diethylamino-hydroxyimino-oxidoazanium Chemical compound CCN(CC)[N+](\[O-])=N\O FOSISNXVGQBIAP-ALCCZGGFSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 230000007730 Akt signaling Effects 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 2
• 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 2
• 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 108090000371 Esterases Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 108010078321 Guanylate Cyclase Proteins 0.000 description 2
• 102000014469 Guanylate cyclase Human genes 0.000 description 2
• 102100024227 High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A Human genes 0.000 description 2
• 101001117259 Homo sapiens High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A Proteins 0.000 description 2
• 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 2
• 101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
• 102000038030 PI3Ks Human genes 0.000 description 2
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
• 229920002732 Polyanhydride Polymers 0.000 description 2
• 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 239000005864 Sulphur Chemical group 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000001466 anti-adreneric effect Effects 0.000 description 2
• 230000002236 anti-hypertrophic effect Effects 0.000 description 2
• WZSUOQDIYKMPMT-UHFFFAOYSA-N argon krypton Chemical compound [Ar].[Kr] WZSUOQDIYKMPMT-UHFFFAOYSA-N 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000003190 augmentative effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
• 102100037093 cGMP-inhibited 3',5'-cyclic phosphodiesterase A Human genes 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000013522 chelant Substances 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000037326 chronic stress Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000001246 colloidal dispersion Methods 0.000 description 2
• 238000004737 colorimetric analysis Methods 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 230000009989 contractile response Effects 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 210000000172 cytosol Anatomy 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000000586 desensitisation Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 230000009986 erectile function Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• 210000002064 heart cell Anatomy 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 229910001425 magnesium ion Inorganic materials 0.000 description 2
• 229910001437 manganese ion Inorganic materials 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 229960004011 methenamine Drugs 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000011201 multiple comparisons test Methods 0.000 description 2
• 239000002840 nitric oxide donor Substances 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• 102000005681 phospholamban Human genes 0.000 description 2
• 108010059929 phospholamban Proteins 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920001281 polyalkylene Polymers 0.000 description 2
• 229920002451 polyvinyl alcohol Polymers 0.000 description 2
• ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• 239000003531 protein hydrolysate Substances 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 239000012723 sample buffer Substances 0.000 description 2
• 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000000391 smoking effect Effects 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000000304 vasodilatating effect Effects 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
• XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• FTKRTAOMTPRFHJ-UHFFFAOYSA-N 2-[1-[7-[(3-chloro-4-methoxyphenyl)methylamino]-3-propyl-2h-pyrazolo[4,3-d]pyrimidin-5-yl]ethoxy]acetic acid Chemical compound N=1C(C(C)OCC(O)=O)=NC2=C(CCC)NN=C2C=1NCC1=CC=C(OC)C(Cl)=C1 FTKRTAOMTPRFHJ-UHFFFAOYSA-N 0.000 description 1
• LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• KJJPAVCZQWWWMM-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-[1]benzothiolo[2,3-d]pyrimidin-2-yl]cyclohexane-1-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C2CCC(CC2)C(O)=O)=NC2=C1C1=CC=CC=C1S2 KJJPAVCZQWWWMM-UHFFFAOYSA-N 0.000 description 1
• UZTKBZXHEOVDRL-UHFFFAOYSA-N 5-[2-ethoxy-5-(piperazine-1-sulfonyl)phenyl]-1-methyl-3-propyl-1h,6h,7h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N=2)=O)=C1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCNCC1 UZTKBZXHEOVDRL-UHFFFAOYSA-N 0.000 description 1
• PYHXQKPRNCIMHW-UHFFFAOYSA-N 5-[4-[(3-chloro-4-methoxyphenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl]pentanoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CCCCC(O)=O)=NC2=C1C(CCCC1)=C1S2 PYHXQKPRNCIMHW-UHFFFAOYSA-N 0.000 description 1
• SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 102100023818 ADP-ribosylation factor 3 Human genes 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000027896 Aortic valve disease Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 108010006835 Atrial Natriuretic Factor Receptors Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• 102100024316 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Human genes 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
• 229920002284 Cellulose triacetate Polymers 0.000 description 1
• 229920002101 Chitin Polymers 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 102000002585 Contractile Proteins Human genes 0.000 description 1
• 108010068426 Contractile Proteins Proteins 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
• 206010013142 Disinhibition Diseases 0.000 description 1
• 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
• 102100036367 Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Human genes 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
• 101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 1
• 101001072029 Homo sapiens Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Proteins 0.000 description 1
• 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010058987 Inferior vena caval occlusion Diseases 0.000 description 1
• 102000016924 KATP Channels Human genes 0.000 description 1
• 108010053914 KATP Channels Proteins 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 206010024119 Left ventricular failure Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000011682 Mitral valve disease Diseases 0.000 description 1
• 206010028594 Myocardial fibrosis Diseases 0.000 description 1
• 108091005975 Myofilaments Proteins 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010020346 Polyglutamic Acid Proteins 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102100021557 Protein kinase C iota type Human genes 0.000 description 1
• LFMFPKKYRXFHHZ-UHFFFAOYSA-N R24 Chemical compound C1=C(Cl)C(C)=CC=C1NC1=NC(N)=C(C=CC=C2)C2=N1 LFMFPKKYRXFHHZ-UHFFFAOYSA-N 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
• CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
• 241001116459 Sequoia Species 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 206010071436 Systolic dysfunction Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 208000006906 Vascular Ring Diseases 0.000 description 1
• 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 229920002494 Zein Polymers 0.000 description 1
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
• CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000008649 adaptation response Effects 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 239000000785 adrenergic beta-1 receptor agonist Substances 0.000 description 1
• 239000000808 adrenergic beta-agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229920013820 alkyl cellulose Polymers 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000003257 anti-anginal effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 239000000823 artificial membrane Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000009530 blood pressure measurement Methods 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 1
• 230000003222 cGMP degradation Effects 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000001925 catabolic effect Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 229920003086 cellulose ether Polymers 0.000 description 1
• 229920006218 cellulose propionate Polymers 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000000546 chi-square test Methods 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 150000001840 cholesterol esters Chemical class 0.000 description 1
• 229940059329 chondroitin sulfate Drugs 0.000 description 1
• 231100000762 chronic effect Toxicity 0.000 description 1
• 230000002057 chronotropic effect Effects 0.000 description 1
• 229940117229 cialis Drugs 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000009091 contractile dysfunction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 210000005226 corpus cavernosum Anatomy 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000000000 cycloalkoxy group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 230000004882 diastolic arterial blood pressure Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
• SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 238000002565 electrocardiography Methods 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000000295 emission spectrum Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000000695 excitation spectrum Methods 0.000 description 1
• 229950000484 exisulind Drugs 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000037417 hyperactivation Effects 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000013101 initial test Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 239000012931 lyophilized formulation Substances 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 125000005395 methacrylic acid group Chemical group 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 210000003632 microfilament Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
• 230000001452 natriuretic effect Effects 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 230000008035 nerve activity Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000012633 nuclear imaging Methods 0.000 description 1
• 230000017111 nuclear migration Effects 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001476 pentoxifylline Drugs 0.000 description 1
• 230000036513 peripheral conductance Effects 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
• 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
• 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
• 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
• 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 108010011110 polyarginine Proteins 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920000139 polyethylene terephthalate Polymers 0.000 description 1
• 239000005020 polyethylene terephthalate Substances 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920000182 polyphenyl methacrylate Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920001290 polyvinyl ester Polymers 0.000 description 1
• 229920001289 polyvinyl ether Polymers 0.000 description 1
• 230000009090 positive inotropic effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 208000010625 pulmonary valve disease Diseases 0.000 description 1
• 230000035485 pulse pressure Effects 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 102000009099 rhoA GTP Binding Protein Human genes 0.000 description 1
• 108010087917 rhoA GTP Binding Protein Proteins 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 229940103087 sildenafil 100 mg Drugs 0.000 description 1
• 229960002639 sildenafil citrate Drugs 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• 235000021055 solid food Nutrition 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000007447 staining method Methods 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 238000009662 stress testing Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 108020001568 subdomains Proteins 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229960003080 taurine Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
• RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000001515 vagal effect Effects 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 230000006438 vascular health Effects 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229940094720 viagra Drugs 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000005019 zein Substances 0.000 description 1
• 229940093612 zein Drugs 0.000 description 1
• 238000007805 zymography Methods 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1